Outcomes and endpoints in cancer trials: bridging the divide.

@article{Wilson2015OutcomesAE,
  title={Outcomes and endpoints in cancer trials: bridging the divide.},
  author={Michelle K Wilson and Deborah E. Collyar and Diana T Chingos and Michael Friedlander and Tony W. Ho and Katherine Karakasis and Stanley B. Kaye and Mahesh K B Parmar and Matthew R. Sydes and Ian F. Tannock and Amit Manulal Oza},
  journal={The Lancet. Oncology},
  year={2015},
  volume={16 1},
  pages={e43-52}
}
Cancer is not one disease. Outcomes and endpoints in trials should incorporate the therapeutic modality and cancer type because these factors affect clinician and patient expectations. In this Review, we discuss how to: define the importance of endpoints; make endpoints understandable to patients; improve the use of patient-reported outcomes; advance endpoints to parallel changes in trial design and therapeutic interventions; and integrate these improvements into trials and practice. Endpoints… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 18 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…